Acadia Pharmaceuticals Stock Today
| ACAD Stock | USD 16.29 0.08 0.49% |
Performance0 of 100
| Odds Of DistressLess than 8
|
ACADIA Pharmaceuticals is trading at 16.29 as of the 28th of November 2024, a 0.49 percent increase since the beginning of the trading day. The stock's lowest day price was 16.15. ACADIA Pharmaceuticals has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for ACADIA Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of September 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of May 2004 | Category Healthcare | Classification Health Care |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. The company has 166.39 M outstanding shares of which 10.24 M shares are presently shorted by private and institutional investors with about 7.48 trading days to cover. More on ACADIA Pharmaceuticals
Moving against ACADIA Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ACADIA Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Stephen JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, OMX Stockholm Mid, OMX Stockholm, NASDAQ Composite, ARCA Biotechnology, OMX Stockholm GI, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsACADIA Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ACADIA Pharmaceuticals' financial leverage. It provides some insight into what part of ACADIA Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACADIA Pharmaceuticals (ACAD) is traded on NASDAQ Exchange in USA. It is located in 12830 El Camino Real, San Diego, CA, United States, 92130 and employs 620 people. ACADIA Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.71 B. ACADIA Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 166.39 M outstanding shares of which 10.24 M shares are presently shorted by private and institutional investors with about 7.48 trading days to cover.
ACADIA Pharmaceuticals currently holds about 436.35 M in cash with 16.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.7.
Check ACADIA Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationACADIA Pharmaceuticals secures a total of 166.39 Million outstanding shares. The majority of ACADIA Pharmaceuticals outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in ACADIA Pharmaceuticals to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in ACADIA Pharmaceuticals. Please pay attention to any change in the institutional holdings of ACADIA Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check ACADIA Ownership Details
ACADIA Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Palo Alto Investors, Llc | 2024-09-30 | 2.5 M | |
| First Trust Advisors L.p. | 2024-06-30 | 2.1 M | |
| Tang Capital Management Llc | 2024-09-30 | 1.5 M | |
| Norges Bank | 2024-06-30 | 1.5 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | |
| Voloridge Investment Management, Llc | 2024-09-30 | 1.3 M | |
| Man Group Plc | 2024-09-30 | 1.3 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.3 M | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 1.3 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 42.9 M | |
| Vanguard Group Inc | 2024-09-30 | 13.8 M |
ACADIA Pharmaceuticals Historical Income Statement
ACADIA Stock Against Markets
ACADIA Pharmaceuticals Corporate Management
| Parag PharmD | Senior Franchise | Profile | |
| Elizabeth Thompson | Executive Development | Profile | |
| Bob Mischler | Senior Strategy | Profile | |
| Albert Kildani | Senior Communications | Profile | |
| Douglas MD | Executive Development | Profile | |
| James Kihara | Chief VP | Profile |
Already Invested in ACADIA Pharmaceuticals?
The danger of trading ACADIA Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ACADIA Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ACADIA Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ACADIA Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.